ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with record revenue growth, improved EBITDA, and a better cash position. Challenges remain, such as FDA approval delays for Re-Tain and strategic partner needs, but management is addressing them. The reduction in backlog and net debt, coupled with a focus on First Defense expansion, are positive signs. The market is likely to react positively, considering the company's strategic initiatives and recent financial achievements, despite some uncertainties.
Key Financial Performance
Product Sales (Q2 2025) Increased by 18% or $972,000 year-over-year. The increase was attributed to a period of increased production output, which allowed the company to eliminate its backlog of orders and rebuild inventory and distribution.
Product Sales (First Half 2025) Increased by 14% or $1.8 million year-over-year. The increase was due to improved production capacity and the elimination of order backlogs.
Product Sales (Trailing 12 Months Ended June 30, 2025) Increased by 22% or $5.1 million year-over-year. This was driven by increased production output and the rebuilding of inventory and distribution pipelines.
Gross Margin (Q2 2025) Increased to 44% compared to 22% in Q2 2024. The improvement was due to better production yields and the resolution of contamination and equipment issues.
Gross Margin (First Half 2025) Increased to 43% compared to 28% in the first half of 2024. The improvement was attributed to enhanced production efficiency and the elimination of prior operational challenges.
Gross Margin (Trailing 12 Months Ended June 30, 2025) Increased to 37% compared to 26% in the trailing 12 months ended June 30, 2024. This was due to improved production processes and operational stability.
Adjusted EBITDA (Q2 2025) Increased to $1.4 million compared to negative $619,000 in Q2 2024. The improvement was driven by higher sales and better gross margins.
Adjusted EBITDA (First Half 2025) Increased to $3.7 million compared to negative $161,000 in the first half of 2024. This was due to increased sales and improved operational efficiency.
Adjusted EBITDA (Trailing 12 Months Ended June 30, 2025) Increased to $5.3 million compared to negative $370,000 in the trailing 12 months ended June 30, 2024. The improvement was attributed to higher sales and better cost management.
Cash Position (As of June 30, 2025) Increased to $6 million from $3.8 million as of December 31, 2024. The increase was due to improved financial performance and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
First Defense product line expansion: Investment to increase production capacity for the First Defense product line to support $30 million or more in revenue per year is now complete. New product formats have been introduced, expanding its uses and appeal.
Re-Tain development: Initiating investigational product use studies to test market acceptance in the field over the second half of the year. The product aims to treat subclinical mastitis in cows, offering an alternative to traditional antibiotics and addressing public health concerns.
Market recovery and growth: Eliminated order backlog and rebuilt inventory and distribution. Focused on recovering lost customers and increasing market share.
Production and gross margin improvement: Production output increased, eliminating backlog and rebuilding inventory. Gross margin improved significantly from 22% in Q2 2024 to 44% in Q2 2025.
Adjusted EBITDA growth: Adjusted EBITDA improved to $1.4 million in Q2 2025 from negative $619,000 in Q2 2024. Cash increased to $6 million as of June 30, 2025, from $3.8 million at the end of 2024.
Re-Tain strategic approach: Focused on investigational product use trials, exploring strategic options to offset cash requirements, and investigating alternative uses for manufacturing plant and equipment.
Debt refinancing: Refinanced a portion of bank debt, reducing interest rates and avoiding large balloon payments due in 2026 with a new 5-year note payable through 2030.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Production Capacity Challenges: The process to increase production capacity for the First Defense product line faced contamination events and other challenges, causing delays.
Sales Softening Risk: Refilling the distribution pipeline after an extended backlog provided a temporary boost to sales, but this inventory rebuild is not expected to repeat, potentially leading to a softening in sales during the second half of 2025.
Customer Retention and Market Share: The company must regain customers lost during the period of short product supply and increase market share while avoiding contamination events, equipment breakdowns, and achieving strong production yields.
Re-Tain FDA Approval Delays: The commercial launch of Re-Tain is delayed due to pending FDA approval, lack of a validated aseptic fill solution, and cash constraints.
Milk Processing Compatibility: Re-Tain's success depends on ensuring that its active ingredient, Nisin, does not interfere with milk processing methods, such as cheese and yogurt production.
Short Shelf Life of Inventory: Inventory built during 2022 and 2023 for Re-Tain has a short shelf life, creating risks if market launch is delayed.
Cash Constraints: The company faces cash constraints that impact its ability to produce commercial inventory and fully launch Re-Tain.
Regulatory and Strategic Execution Risks: The company must navigate FDA approval processes, conduct investigational product use trials, and explore strategic options for Re-Tain while managing cash flow and regulatory compliance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company has completed its investment to increase production capacity for the First Defense product line, supporting $30 million or more in revenue per year.
Product Development and Market Launch: Re-Tain investigational product use studies will be conducted in the second half of 2025 to test market acceptance. A full commercial launch of Re-Tain will not proceed until FDA approval is obtained, a validated aseptic fill solution is in place, and adequate cash is available to produce commercial inventory.
Strategic Options for Re-Tain: The company is exploring strategic options for Re-Tain, including offsetting cash requirements and investigating alternative uses for the manufacturing plant and equipment.
Market Trends and Industry Alignment: Re-Tain aligns with industry trends to reduce the use of traditional antibiotics in food-producing animals, addressing public health concerns and sustainability objectives.
Operational Adjustments: The company plans to use existing inventory with a short shelf life for investigational product use studies in collaboration with Michigan State University during the second half of 2025. Data analysis is expected to be completed in the first quarter of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the organic growth excluding the benefit of backlog sales in the first half?
A:Management did not provide a specific number. They mentioned that the backlog at the end of March 2025 was $4 million, which was worked through during the second quarter. Some orders were canceled, and most were filled. They emphasized focusing on GAAP sales and noted that the backlog issue is a one-time event.
Q:Can you provide an update on Re-Tain, including the facility inspection and potential FDA approval delay?
A:Management clarified that ImmuCell passed its inspection without a 483. However, the CMO responsible for aseptically filling the drug substance into tubes has unresolved 483 inspection observations. This issue has been ongoing for over a year, and the timing for resolution is uncertain. The FDA and the CMO are working on it, and it remains the final hurdle for FDA approval.
Q:How much inventory will be expiring in the second half of the year and used for investigational purposes?
A:All of the inventory produced in anticipation of commercial launch will be used for investigational purposes and will not generate revenue. The inventory has already been expensed, so there will be no future P&L impact.
Q:What are the strategic options being pursued for Re-Tain?
A:Management is looking for financial and marketing support to launch Re-Tain commercially. They aim to partner with a larger marketing group to introduce the product and provide financial backing. They are open to flexible negotiations but emphasized the need for support to reduce financial exposure and ensure a successful launch.
Q:Would a distributor be a good partner for Re-Tain?
A:Management believes distributors are essential for distribution but lack the experience, knowledge, and willingness to provide financial support or handle manufacturing. They see a strategic partner as a more likely option.
Q:What is the timing for increasing capacity from 30 to 40?
A:The project to increase capacity is on hold. Management is carefully evaluating timing and cash flows, with no immediate plans to proceed. They are optimistic about needing the increased capacity in the future but are prioritizing cash flow management.
Q:How will the sales team's renewed focus impact the First Defense product line?
A:The sales team is now focused on regaining lost customers and acquiring new business, as they are no longer dealing with short supply issues. They are energized and confident, with sufficient inventory to meet demand.
Q:What are the challenges in rebuilding the reputation of First Defense in the marketplace?
A:The company's reputation was tarnished due to supply shortages, frustrating customers. Management believes the product's efficacy will help regain trust, and they are now ready to ship consistently to meet demand.
Q:Can you provide an update on the new format for First Defense (spray-dried colostrum)?
A:The new format had its first sales in Q2, and management plans to break out its performance in Q3 disclosures. The product targets a new niche, such as large ranches of calf feed, and has shown promising momentum.
Q:How is the company managing frozen colostrum inventory?
A:The company has a strong network of farms providing colostrum and is managing inventory to prevent a return to backlog. Frozen colostrum serves as a security blanket, and the company is balancing cash management with inventory levels.
Q:What progress has been made in reducing net debt and backlog?
A:Backlog has been eliminated, and net debt has been reduced significantly. The company refinanced loans to eliminate a $2 million balloon payment in 2026, spreading it over five years.
Q:What is the company's strategy for growing the beef segment?
A:The beef segment is seasonal and challenging due to its dispersed nature. The company is focusing on marketing campaigns to reach more customers efficiently and leveraging sales reps in key beef areas.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific number for organic growth excluding backlog sales. They also could not provide a timeline for resolving the FDA approval delay for Re-Tain, as it depends on the CMO and FDA. Additionally, they did not disclose the exact amount of expiring inventory or specific details about the timing for increasing capacity from 30 to 40.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Secretary
CFO highlight
Conference Instructions
Director Timothy
EBITA stock
ET ImmuCell
FDA approval
Friday obligation
ImmuCell investment
Instructions event
LLC Conference
LLC Lytham
Lytham Partners
MKH LLC
Officer Rem
Partners Investor
Partners LLC
Partners Listeners
Product sale
Rem Unidentified
Secretary Director
Tain product
Timothy Fiori
Tuesday night
Unidentified George
acceptance
comment
distribution
inventory
month period
noncash
opening
period result
sale Product
sale margin
supply
use
ICCC Transcript
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call reflects strong financial performance with a 28.4% revenue increase and improved margins. Optimistic guidance on manufacturing capacity expansion and strategic focus on the First Defense line further support a positive outlook. Despite challenges in international market entry and increased operating expenses, the growth in domestic sales and effective capacity management are promising. Q&A insights on product differentiation and sales strategy reinforce confidence. Overall, the sentiment is positive, likely leading to a 2% to 8% stock price increase.
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents mixed signals: improved gross margins and domestic sales growth are positive, but supply constraints, competition, and declining international sales offset this. The Q&A reveals management's evasiveness on recurring revenue, raising concerns. Despite operational improvements and no large future write-downs, the lack of guidance on recurring revenue and international market underdevelopment tempers optimism. The neutral sentiment reflects these balanced positives and negatives, with no strong catalysts to drive significant stock movement.
ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call presents a mixed picture: improved gross margins and domestic sales growth are positive, but international sales decline and regulatory delays pose risks. The Q&A highlights effective inventory management and customer engagement, but challenges in supply chain and competitive pressures remain. Despite financial improvements, the lack of new partnerships or strong guidance tempers optimism. Overall, the sentiment is neutral, as positives are balanced by uncertainties.
ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
Positive8-15
The earnings call indicates strong financial performance with record revenue growth, improved EBITDA, and a better cash position. Challenges remain, such as FDA approval delays for Re-Tain and strategic partner needs, but management is addressing them. The reduction in backlog and net debt, coupled with a focus on First Defense expansion, are positive signs. The market is likely to react positively, considering the company's strategic initiatives and recent financial achievements, despite some uncertainties.
ICCC Slides
ICCC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
